Breast Cancer News
In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
The Food and Drug Administration (FDA) has approved denosumab to help prevent bone damage in people with cancer that has spread to the bone tissue.
Living Beyond Breast Cancer Statement on FDA’s Decision to Remove Approval of Avastin for Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) yesterday announced that it plans to begin the process necessary to withdraw approval of Avastin (bevacizumab) as a treatment for metastatic breast cancer. Living Beyond Breast Cancer (LBBC) encourages insurance carriers and the federal government to continue reimbursing payment for Avastin for women currently taking it who are responding to it. Additionally, we strongly encourage the manufacturer to continue its program to assist women in need who are taking Avastin and are responding.
FDA's announcement that it plans to withdraw approval of Avastin in metastatic breast cancer begins a review process that could last several months. Learn about the timeline for a decision, the impact on access and insurance coverage, and how to submit public comments to FDA.
NEW YORK (Reuters Health) - A diagnosis of breast cancer will inevitably sink a woman's mood, but those whose spirits lift over time appear to survive longer, a new study suggests.
NEW YORK (Reuters) - Amgen Inc's new osteoporosis drug denosumab delayed fractures and other bone problems in patients with advanced breast cancer five months longer than Novartis AG's Zometa, according to data from a large clinical trial.
CHAPEL HILL, N.C. (Reuters) - Elizabeth Edwards, a best-selling author and a driving force behind her husband John Edwards' political career before it was destroyed by his infidelity, died on Tuesday at age 61.
LONDON (Reuters) - Britain's healthcare cost agency NICE has rejected Roche's Avastin as a treatment for advanced breast cancer and given a poor assessment of the drug ahead of a decision soon on its status in the key U.S. market.
NEW YORK (Reuters Health) - Breast cancer survivors who struggle with hot flashes may find respite in an antidepressant, according to a new study that suggests the medication should be the go-to drug when the overheating is severe.
ZURICH (Reuters) - European healthcare regulators are reviewing the benefits of Roche's top-selling Avastin drug in breast cancer in the light of fresh clinical data, casting more uncertainty over its prospects.
Lapatinib plus Trastuzumab was more effective than Lapatinib alone for women with HER2 positive advanced breast cancer that progressed on trastuzumab, San Antonio study shows.